Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.

作者信息

Gupta Vineet Govinda, Rangaraju Ranga Rao, Saha Rajat, Bajpai Peush

机构信息

Department of Medical Oncology, Max Super Speciality Hospital, B-2 Basement, Shalimar Bagh, New Delhi, India.

Department of Medical Oncology, Max Super Speciality Hospital, Patparganj, New Delhi, India.

出版信息

J Gastrointest Cancer. 2019 Dec;50(4):943-946. doi: 10.1007/s12029-018-0130-3.

DOI:10.1007/s12029-018-0130-3

PMID:29961919

Abstract

摘要

相似文献

[1]

Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.

J Gastrointest Cancer. 2019-12

[2]

Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.

Clin Exp Dermatol. 2015-7

[3]

[Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas].

Dtsch Med Wochenschr. 2011-5

[4]

For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens?

J Clin Oncol. 2007-9-20

[5]

It is time for a proper staging system for adenocarcinoma of the gastroesophageal junction.

J Clin Oncol. 2007-3-1

[6]

[Positron emission tomography in tumors of the upper gastrointestinal tract: controversial value].

Dtsch Med Wochenschr. 2011-5

[7]

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Gastric Cancer. 2019-3-25

[8]

Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.

J Gastrointest Cancer. 2019-12

[9]

Potentially Curable Cancers of the Esophagus and Stomach.

Mayo Clin Proc. 2016-9

[10]

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.

Lancet Oncol. 2015-4-14

引用本文的文献

[1]

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.

Front Oncol. 2023-6-12

本文引用的文献

[1]

Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.

Clin Ther. 2017-11-27

[2]

Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China.

Oncotarget. 2017-8-1

[3]

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.

Cancer Res Treat. 2017-1-3

[4]

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.

Oncotarget. 2016-4-26

[5]

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Lancet Oncol. 2015-8

[6]

Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].

Urol Oncol. 2016-5

[7]

Update on metastatic gastric and esophageal cancers.

J Clin Oncol. 2015-4-27

[8]

Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.

Mol Cancer Ther. 2014-9-23

[9]

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Lancet Oncol. 2014-9-17

[10]

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

J Clin Oncol. 2014-9-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献